Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases

Journal of Clinical Oncology

Volumn 31, Issue 16, 2013, Pages 1931-1938

  Ye, Le Chi ^a   Liu, Tian Shu ^a   Ren, Li ^a   Wei, Ye ^a   Zhu, De Xiang ^a   Zai, Sheng Yong ^a   Ye, Qing Hai ^a   Yu, Yiyi ^a   Xu, Bo ^a   Qin, Xin Yu ^a   Xu, Jianmin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN;

ACNE; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LIVER RESECTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PEROPERATIVE COMPLICATION; PRIMARY TUMOR; PRIORITY JOURNAL; RADICAL RESECTION; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL TIME; VOMITING; WEDGE RESECTION; WILD TYPE; ASIAN; CHINA; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; GENETICS; KAPLAN MEIER METHOD; LIVER TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; CHINA; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RESEARCH DESIGN; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84880736194     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.8308     Document Type: Article

References (31)

1. Steele G Jr, Ravikumar TS: Resection of hepatic metastases from colorectal cancer: Biologic perspective. Ann Surg 210:127-138, 1989
2. Foster JH: Treatment of metastatic disease of the liver: A skeptic's view. Semin Liver Dis 4:170-179, 1984
3. Stangl R, Altendorf-Hofmann A, Charnley RM, et al: Factors influencing the natural history of colorectal liver metastases. Lancet 343:1405-1410, 1994
4. Van Cutsem E, Nordlinger B, Adam R, et al: Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42:2212-2221, 2006
5. Goldberg RM, Rothenberg ML, Van Cutsem E, et al: The continuum of care: A paradigm for the management of metastatic colorectal cancer. Oncologist 12:38-50, 2007
6. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174, 2008
7. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
8. Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417, 2009
9. Petrelli F, Barni S: Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: A meta-analysis. Int J Colorectal Dis 27:997-1004, 2012
10. Abdalla EK, Vauthey JN, Ellis LM, et al: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818-825, 2004; discussion 825-827
11. Choti MA, Sitzmann JV, Tiburi MF, et al: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759-766, 2002
12. Tabernero J, Ciardiello F, Rivera F, et al: Cetuximab administered once every second week to patients with metastatic colorectal cancer: A two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol 21:1537-1545, 2010
13. Charnsangavej C, Clary B, Fong Y, et al: Selection of patients for resection of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 13:1261-1268, 2006
14. Pawlik TM, Schulick RD, Choti MA: Expanding criteria for resectability of colorectal liver metastases. Oncologist 13:51-64, 2008
15. Garden OJ, Rees M, Poston GJ, et al: Guidelines for resection of colorectal cancer liver metastases. Gut 55:iii1-iii8, 2006 (suppl 3)
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
17. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
18. Ayez N, Lalmahomed ZS, van der Pool AE, et al: Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol 18:2757-2763, 2011
19. Nordlinger B, Guiguet M, Vaillant JC, et al: Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients-Association Française de Chirurgie. Cancer 77:1254-1262, 1996
20. Choti MA: Chemotherapy-associated hepatotoxicity: Do we need to be concerned? Ann Surg Oncol 16:2391-2394, 2009
21. Adam R: Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases. Ann Oncol 14:ii13-ii16, 2003 (suppl 2)
22. Delaunoit T, Alberts SR, Sargent DJ, et al: Chemotherapy permits resection of metastatic colorectal cancer: Experience from Intergroup N9741. Ann Oncol 16:425-429, 2005
23. Bokemeyer C, Bondarenko I, Hartmann JT, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 22:1535-1546, 2011
24. Jones RP, Vauthey JN, Adam R, et al: Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg 99:1263-1269, 2012
25. Folprecht G, Gruenberger T, Bechstein WO, et al: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 11:38-47, 2010
26. Maughan TS, Adams RA, Smith CG, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 377:2103-2114, 2011
27. Tveit K, Guren T, Glimelius B, et al: Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII study. J Clin Oncol 30:1755-1762, 2012
28. Bokemeyer C, Bondarenko I, Hartmann JT, et al: Biomarkers predictive for outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line FOLFOX4 plus or minus cetuximab: Updated data from the OPUS study. J Clin Oncol 28, 2010 (suppl; abstr 428)
29. Lièvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379, 2008
30. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
31. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008